Taro Pharmaceutical Industries has posted strong net profit growth of 70 per cent during the fourth quarter ended March 2015 to US$ 153 million from $90 million in the similar period of last year. Its net sales up by 30.5 per cent to $244 million from $187 million. With smart improvement in earnings, EPS worked out to $3.56 as against $2.10 in the last period. Its R&D expenses raised to $23.9 million from $13.1 million and selling, marketing, general and administrative expenses declined by 16.5 per cent to $22.2 million from $26.6 million.
For the full year ended March 2015, Taro's net sales increased by 13.7 per cent to $863 million from $759 million in the previous year and net profit went up by 34.6 per cent to $486 million from 361 million. EPS for the year 2014-15 worked out to $11.32 as against $8.15 in the last year. Its R&D expenditure increased by 18.2 per cent to $65.5 million from $55.4 million. Income through settlements and loss contingencies was at $4.2 million as against expenses of $2.6 million in the previous year. Its total debt decreased to $12 million due to paying-off of its debentures with institutional holders.
During 2014-15 company filed five ANDAs and a one NDA with the US FDA and its cumulative filings reached at 12 ANDAs. The company is awaiting approval for 35 ANDAs and one NDA.
